Iovance Biotherapeutics/$IOVA
1D1W1MYTD1Y5YMAX
Capital at risk
About Iovance Biotherapeutics
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.
- Ticker
- $IOVA
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 975
- Headquarters
- San Carlos, United States
- Website
- www.iovance.com
IOVA Metrics
BasicAdvanced
$4.2B
-
-$0.71
0.70
-
Price and volume
Market cap
$4.2B
Beta
0.7
52-week high
$9.41
52-week low
$1.76
Average daily volume
17M
Financial strength
Current ratio
4.345
Quick ratio
3.742
Long term debt to equity
0.059
Total debt to equity
0.063
Interest coverage (TTM)
-134.50%
Profitability
EBITDA (TTM)
-259.603
Gross margin (TTM)
48.40%
Net profit margin (TTM)
-89.09%
Operating margin (TTM)
-91.14%
Effective tax rate (TTM)
1.45%
Revenue per employee (TTM)
$330,000
Management effectiveness
Return on assets (TTM)
-20.31%
Return on equity (TTM)
-40.36%
Valuation
Price to revenue (TTM)
11.815
Price to book
5.76
Price to tangible book (TTM)
8.98
Price to free cash flow (TTM)
-12.954
Free cash flow yield (TTM)
-7.72%
Free cash flow per share (TTM)
-0.723
Growth
Revenue change (TTM)
34.55%
Earnings per share change (TTM)
-42.71%
3-year revenue growth (CAGR)
1,009.40%
3-year earnings per share growth (CAGR)
-31.56%
10-year earnings per share growth (CAGR)
-0.04%
What the Analysts think about IOVA
Analyst ratings (Buy, Hold, Sell) for Iovance Biotherapeutics stock.
Analyst projections of the future price of Iovance Biotherapeutics stock.
Bulls say / Bears say
Iovance’s lifileucel TIL therapy demonstrated favorable safety and efficacy in its inaugural soft tissue sarcoma trial, with plans to initiate a single-arm registrational study in second-line undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma in Q2 2026 (Reuters).
The FDA clearance of the IND application for IOV-5001, an IL-12 tethered next-generation TIL therapy, positions Iovance to expand its pipeline into a Phase 1/2 basket trial addressing multiple solid tumors in H2 2026 (Reuters).
In the first half of 2026, Iovance secured net proceeds of $143.6 million from its “at the market” equity program, bolstering liquidity to support the commercial launch of Amtagvi® and ongoing clinical programs (SEC).
Continued high cash burn persisted as Iovance used $132.9 million in operating activities in H1 2026, underscoring reliance on external funding absent sustainable revenue streams (SEC).
The filing of a mixed shelf prospectus for up to $89.7 million of common stock signals potential future equity dilution, which may weigh on shareholder value (Reuters).
Replimune’s August 6, 2026 FDA accelerated approval of Tudriqev™ for advanced melanoma introduces significant competition in the solid tumor immunotherapy space, potentially eroding Iovance’s market share for lifileucel in melanoma indications (Reuters).
Data summarised monthly by Lightyear AI. Last updated on 29 Aug 2026.
IOVA Financial Performance
Revenues and expenses
IOVA Earnings Performance
Company profitability
Upcoming events
No upcoming events
IOVA News
AllArticlesVideos
Funds containing IOVA
AllUSDEURGBP
Fund name | Fund size | $IOVA weighting |
|---|---|---|
iShares Healthcare Innovation$HEAL | $1.4B | 0.36% |
iShares Healthcare Innovation€2B78 | €1.2B | 0.36% |
iShares Healthcare Innovation£DRDR | £1B | 0.36% |
iShares Ageing Population€AGED | €822M | 0.29% |
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.28% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.